Cefoperazone--comparison of the in vitro effects and pharmacokinetic indicators with clinical results
Kittnar, E.; Hejzlar, M.; Pellar, T.; Silarová, J.; Procházka, M.; Vyhnálek, F.; Fára, M.; Königová, R.; Broz, J.; Havlík, J.
Vnitrni Lekarstvi 34(12): 1178-1183
1988
ISSN/ISBN: 0042-773X PMID: 3222926 Document Number: 323959
Document emailed within 1 workday
Related Documents
Kouda, M.; Kumagai, I.; Kobayashi, J.; Sugai, R.; Matsuzaki, H. 1991: Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin Japanese Journal of Antibiotics 44(2): 130-139Romano, G.; Facchini, G.; Savino, B.; Santoro, A.; Manfredini, S.; Ruffilli, M.P.; Tesauro, B. 1986: Use of cefoperazone in peroperative prophylaxis in hepato-biliary surgery. Pharmacokinetic and clinical evaluations Minerva Chirurgica 41(23-24): 2045-2049
Aksoy, A.M.; Ozsan, M.; Ural, O.; Ekmen, H. 1993: In vitro susceptibility to cefoperazone and sulbactam/cefoperazone combination of bacterial strains isolated from various patient materials Mikrobiyoloji Bulteni 27(3): 216-220
Koga, H.; Tomono, K.; Hirakata, Y.; Kohno, S.; Abe, K.; Kawamoto, S.; Kusano, S.; Tanaka, K.; Morikawa, N.; Sugiyama, H.; Katsumata, T.; Sasayama, K.; Shimoguchi, K.; Hashimoto, A.; Matsumoto, Y.; Inoue, Y.; Ishiguro, M.; Hori, H.; Mashimoto, H.; Dotsu, Y.; Tanaka, H.; Imamura, Y.; Kanda, T.; Hara, K. 1996: Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase Japanese Journal of Antibiotics 49(8): 800-807
Kukes, V.G.; Volkov, R.I.; Ibadova, D.; Shokhor, V.I. 1985: Results of the pharmacokinetic, pharmacodynamic and clinical studies of digoxin use Terapevticheskii Arkhiv 57(12): 59-62
Gruber, H.E.; Norton, H.J.; Leslie, K.; Hanley, E.N. 2001: Clinical and demographic prognostic indicators for human disc cell proliferation in vitro: pilot study Spine 26(21): 2323-2327
Nielsen, K.T.; Madsen, P.O. 1989: Cefoperazone or cefoperazone-sulbactam as perioperative antibiotic prophylaxis in transurethral surgery Journal of ChemoTherapy 1(4 Suppl): 1010-1011
Faggioli, M. 1978: Erythromycin combined with balsamic agents in oral and rectal administration: results in pharmacokinetic and clinical trials La Clinica Terapeutica 84(2): 141-150
Chlebowski, R.T.; Gota, C.H.; Chan, K.K.; Weiner, J.M.; Block, J.B.; Bateman, J.R. 1982: Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer Cancer Research 42(11): 4827-4830
Sutter, V.L.; Kwok, Y.Y. 1981: Factors affecting the in vitro activity of cefoperazone against the Bacteroides fragilis group Antimicrobial Agents and Chemotherapy 20(6): 723-725
Chittawatanarat, K.; Sataworn, D.; Thongchai, C.; Permpikul, C.; Chaiwat, O.; Kongsayreepong, S.; Vorrakitpokatorn, P.; Wilaichone, W.; Bunburaphong, T.; Saengchote, W.; Morakul, S.; Thawitsri, T.; Sitthipan, C.; Sombunvibul, W.; Chatrkaw, P.; Poonyathawon, S.; Watanathum, A.; Fuengfoo, P.; Satawom, D.; Wongsa, A.; Piyavechviratana, K.; Rungruanghiranya, S.; Pothirat, C.; Deesomchok, A.; Chittawatanarat, K.; Patjanasoontom, B.; Bhurayanontachai, R.; Champunut, R.; Chuachamsai, N.; Thongchai, C. 2014: Effects of ICU characters, human resources and workload to outcome indicators in Thai ICUs: the results of ICU-RESOURCE i study Journal of the Medical Association of Thailand 97(Suppl 1): S22-S30
Joly-Guillou, M.L.; Bergogne-Berezin, E.; Verin-Prevost, C. 1984: In vitro comparative activity of 4 beta-lactams against Pseudomonas aeruginosa. Role of cefoperazone Pathologie-Biologie 32(5): 408-411
Rezvan, S.P.; Sidorenko, S.V.; Budanov, S.V. 1995: Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms Antibiotiki i Khimioterapiia 40(4): 25-29
Frongillo, R.F.; Moretti, M.V.; Bittarelli, C.; Moretti, A. 1983: Effect of protein concentration and blood clots on the "in vitro" anti-Pseudomonas aeruginosa activity of cefoperazone Bollettino dell'Istituto Sieroterapico Milanese 62(5): 417-419
Mobbs, J.P.; Balant, L.; Revillard, C.; Favre, H. 1977: Side effects of nalidixic acid in a patient with severe renal failure. Clinical study and proposal of a pharmacokinetic model Schweizerische Medizinische Wochenschrift 107(9): 300-306
Buchta, V.ír.; Navrátilová, L.; Förstl, M.; Kubanová, P. 2004: Comparison of the results of in vitro antifungal susceptibility testing using the Fungitest kit and the disc diffusion test Klinicka Mikrobiologie a Infekcni Lekarstvi 10(2): 80-87
Kumano, K.; Nishida, N.; Hayashi, T.; Kasuga, C.; Watanabe, Y.; Yasuda, T.; Saikawa, I. 1983: In vivo effects of cefoperazone in local infection Japanese Journal of Antibiotics 36(12): 3450-3455
Ganser, A.L.; Kirschner, D.A. 1985: The interaction of mercurials with myelin: comparison of in vitro and in vivo effects Neurotoxicology 6(1): 63-77
Scudla, V.; Wiedermann, B.; Wiedermann, D.; Indrák, K. 1984: Significance of prognostic indicators in multiple myeloma. I. Clinical, biochemical and radiographic indicators Vnitrni Lekarstvi 30(12): 1145-1155
1982: Clinical therapeutic effects of compound "Xiaolijun" in treating acute and chronic bacillary dysentery and in its bacillicidal effects in vitro Zhonghua Yi Xue Za Zhi 62(6): 354-357